PBIMA - PES
Neo7logix PES (Personalized Edited Sequence) is registered as a provisional patent with the USPTO as an integral part of PBIMA (Precision-Based Immunomolecular Augmentation). Neo7logix’s unification API is also known as NEO7UAPI.
Neo7Logix’s precision profiling platform to select final pooled sequence immune editing design of the patient matching sequences specific to the patient’s disease but more importantly, unique to that patients’ immune defense and regulatory requirements. The focal strength of PES is the activation of natural cell and humoral defense and regulation using the patient’s prime edited sequences to initiate sustained immunity against disease.